We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Ino7.0
Inositol Research
Probably helps
183 peer-reviewed studies
What the evidence says
Mixed evidence
Studies are split: Inositol helped in 3 of 7 cases, with the rest inconclusive or showing no benefit.
Most evidence is from high-quality meta-analyses and randomised trials published 1986–2026 with a typical study size of 612 participants.
Based on 180 studies · 42 meta-analyses · 100 RCTs · 39,240 total participants
Confidence
High confidence
What the studies found
3helped3unclear1didn't help· 173 more without graded effect data
By outcome
Women's healthMixed: one PCOS meta-analysis found better hormone and metabolic markers, while the 2023 guideline review called the evidence limited and inconclusive · 4-8 weeks · May help reduce menstrual discomfort and PMS symptoms · 1-3 cycles
Probably helps170 studies
Glucose & metabolicImproved insulin sensitivity, especially in PCOS · 4-12 weeks · Improves insulin signalling, especially in PCOS and metabolic syndrome · 8-12 weeks
Mixed evidence164 studies
Fertility & reproductiveIn women with PCOS trying to conceive, inositol raised ovulation rates with moderate certainty, though the review behind the 2023 international PCOS guideline calls the overall evidence limited and inconclusive. · 4-12 weeks
Too few graded studies38 studies
Therapeutic & clinical
Too few graded studies27 studies
Weight managementBody composition support, especially in PCOS · 4-12 weeks
Too few graded studies18 studies
Depression & moodImproved ovulation and hormone balance in PCOS · 3-6 months
Too few graded studies13 studies
Anxiety & stressSignificant reduction in anxiety and panic symptoms · 4-6 weeks
Too few graded studies13 studies
Men's vitality
Too few graded studies8 studies
Skin health
Too few graded studies8 studies
Safety profile
Too few graded studies6 studies
Heart & blood pressure
Too few graded studies5 studies
Cholesterol & lipids
Too few graded studies3 studies
Cognitive function
Too few graded studies2 studies
By the numbers
Pulled from 47 studies with measurable effects
Likely real effects
50%
across studies
People studied
39k
typical study: 612 people
Strongest designs
142
42 pooled, 100 randomised
Showed benefit
43%
3/7 studies
How long studies ran
1–3 months
3
Populations Studied
Women with PCOS8
Pregnant women4
Women with polycystic ovary syndrome3
Women with ovarian aging1
Active research area
72 studies in the last 5 years · Latest meta-analysis: 2026
198620062026
1PCOS symptoms improvementMeta-AnalysisCited 6×n=5,501 · very large study2025
In plain English: Chromium, inositol, and Omega-3 were found to be beneficial for improving lipid profile.
Zhao G et al. · Reproductive biology and endocrinology : RB&E (2025)
Inositol significantly decreased total cholesterol and triglyceride levels, while curcumin was most effective in improving low-density and high-density lipoprotein cholesterol levels.
Chromium, inositol, and Omega-3 were found to be beneficial for improving lipid profile.
For improving obesity, sex hormone levels, inflammatory factors and oxidative stress indicators of PCOS patients, carnitine, chromium, and soy isoflavones are effective options, respectively.
2Gestational diabetes preventionMeta-AnalysisCited 30×n=1,319 · large study2023
In plain English: Evidence from seven studies shows that antenatal dietary supplementation with myo-inositol during pregnancy may reduce the incidence of gestational diabetes, hypertensive disorders of pregnancy and preterm birth.
Motuhifonua SK et al. · The Cochrane database of systematic reviews (2023)
Large benefit
← WorseNo effectBetter →
For the primary neonatal outcomes, only one study measured the risk of a large-for-gestational-age infant and found myo-inositol was associated with both appreciable benefit and harm (RR 1.40, 95% CI 0.65 to 3.02; 1 study, 234 infants; low-certainty evidence).
Further, myo-inositol may result in little to no difference in caesarean section (RR 0.91, 95% CI 0.77 to 1.07; 4 studies, 829 women; low-certainty evidence).
For the secondary neonatal outcomes, meta-analysis showed no neonatal hypoglycaemia (RR 3.07, 95% CI 0.90 to 10.52; 4 studies; 671 infants; very low-certainty evidence).
3Body weight and BMI reductionMeta-AnalysisCited 12×n=2,362 · very large study2023
In plain English: Carnitine was relatively effective in reducing body mass, while chromium, Omega-3, and selenium were beneficial for improving glucose metabolism.
Hu X et al. · PeerJ (2023)
The network meta-analysis showed that carnitine, inositol, and probiotics reduced body weight and body mass index (BMI) compared to placebo, and carnitine outperformed the other supplements (SUCRAs: 96.04%, 97.73%, respectively).
Omega-3 lowered fasting blood glucose (FBG) (SUCRAs: 93.53%), and chromium reduced fasting insulin (FINS) (SUCRAs: 72.90%); both were superior to placebo in improving insulin resistance index (HOMA-IR), and chromium was more effective than Omega-3 (SUCRAs: 79.99%).
Selenium was potent in raising the quantitative insulin sensitivity index (QUICKI) (SUCRAs: 87.92%).
4Clinical pregnancy ratesMeta-AnalysisCited 38×n=2,617 · very large study2024
In plain English: The results showed that use of antioxidants not only significantly increased the number of retrieved oocytes and high-quality embryo rates but also reduced the dose of gonadotropin, contributing to...
Shang Y et al. · Advances in nutrition (Bethesda, Md.) (2024)
The results showed that use of antioxidants not only significantly increased the number of retrieved oocytes and high-quality embryo rates but also reduced the dose of gonadotropin, contributing to higher clinical pregnancy rates.
Appropriate antioxidant treatment should be offered at a low dose according to the patient's age and ovarian reserve.
5IVF/ICSI outcomes and OHSS reductionMeta-AnalysisCited 5×n=1,827 · large study2024
In plain English: Metformin and myoinositol may reduce OHSS risk in PCOS patients but did not significantly improve pregnancy outcomes.
Lin L et al. · Journal of ovarian research (2024)
Huge benefit
← WorseNo effectBetter →
Myoinositol was linked to a shorter gonadotropin duration (SMD = -1.21, 95% CI -2.03 to -0.38) and fewer side effects (OR = 0.23, 95% CI 0.06-0.83) compared to controls.
Metformin led to lower E2 levels, a higher number of mature oocytes, and increased side effects (SMD = -376.52, 95% CI -610.83 to -142.22; SMD = 2.23, 95% CI 0.36-4.10; OR = 6.85, 95% CI 4.32-10.86) than controls.
Metformin and myoinositol may reduce OHSS risk in PCOS patients but did not significantly improve pregnancy outcomes.
6PCOS managementMeta-AnalysisCited 33×n=2,230 · very large study2024
In plain English: The evidence supporting the use of inositol in the management of PCOS is limited and inconclusive.
Fitz V et al. · The Journal of clinical endocrinology and metabolism (2024)
Systematic review of 30 trials (2,230 women with PCOS, 19 pooled) of inositol alone or with other therapies, done for the 2023 international PCOS guideline.
Myo-inositol or D-chiro-inositol may help some metabolic measures and D-chiro-inositol may help ovulation, but inositol may have no effect on other outcomes, and metformin may improve waist-hip ratio and hirsutism more than inositol.
Myo-inositol likely causes fewer gastrointestinal adverse events than metformin, and the authors judge the overall evidence for inositol in PCOS limited and inconclusive.
7Regular menstrual cycle in PCOSMeta-AnalysisCited 79×n=1,691 · large study2023
In plain English: Inositol is an effective and safe treatment in PCOS.
Greff D et al. · Reproductive biology and endocrinology : RB&E (2023)
Huge harm
← WorseNo effectBetter →
In patients treated with inositols, the risk (CI: 1.13; 2.85) of having a regular menstrual cycle was found by 1.79 higher than in the case of placebo.
8Menstrual frequency improvementMeta-AnalysisCited 80×n=1,079 · large study2021
In plain English: Ours is the first study to report that for women with PCOS, myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone.
Compared with metformin, treatment with myo-inositol + D-chiro-inositol was associated with a greater improvement in menstrual frequency (odds ratio 14.70 [95% confidence interval (CI) 2.31-93.58]).
Ours is the first study to report that for women with PCOS, myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone.
Myo-inositol combined with D-chiro-inositol is particularly efficacious in menstrual recovery.
9Cycle regularization in PCOSMeta-AnalysisCited 1×n=388 · medium study2025
In plain English: In this meta-analysis of RCTs, combination therapy was associated with cycle regularization and reduction in hirsutism and LH/FSH ratio compared to metformin monotherapy.
Kelly FA et al. · Endocrine (2025)
Differences in acne (p = 0.58), body mass index (p = 0.13), fasting blood glucose (p = 0.07) and HOMA-IR (p = 0.25) were not statistically significant.
In this meta-analysis of RCTs, combination therapy was associated with cycle regularization and reduction in hirsutism and LH/FSH ratio compared to metformin monotherapy.
Further studies are needed to clarify the true benefits of the use of inositol in PCOS treatment.
10Live birth ratesMeta-AnalysisCited 218×n=4,451 · very large study2017
In plain English: Our updated review suggests that metformin alone may be beneficial over placebo for live birth, although the evidence quality was low.
Morley LC et al. · The Cochrane database of systematic reviews (2017)
Metformin versus placebo or no treatmentThe evidence suggests that metformin may improve live birth rates compared with placebo (OR 1.59, 95% CI 1.00 to 2.51, 4 studies, 435 women, I2 = 0%, low-quality evidence).
There was no clear evidence of a difference in miscarriage rates (OR 1.08, 95% CI 0.50 to 2.35, 4 studies, 748 women, I2 = 0%, low-quality evidence).
However, the combined therapy group had higher rates of clinical pregnancy (OR 1.59, 95% CI 1.27 to 1.99, 16 studies, 1529 women, I2 = 33%, moderate-quality evidence) and ovulation (OR 1.57, 95% CI 1.28 to 1.92, 21 studies, 1624 women, I2 = 64%, moderate-quality evidence).
11Live birth rateMeta-AnalysisCited 114×n=7,760 · very large study2020
In plain English: In this review, there was low- to very low-quality evidence to show that taking an antioxidant may benefit subfertile women.
Showell MG et al. · The Cochrane database of systematic reviews (2020)
Due to the very low-quality of the evidence we are uncertain whether antioxidants improve live birth rate compared with placebo or no treatment/standard treatment (odds ratio (OR) 1.81, 95% confidence interval (CI) 1.36 to 2.43; P < 0.001, I2 = 29%; 13 RCTs, 1227 women).
This suggests that among subfertile women with an expected live birth rate of 19%, the rate among women using antioxidants would be between 24% and 36%.
Low-quality evidence suggests that antioxidants may improve clinical pregnancy rate compared with placebo or no treatment/standard treatment (OR 1.65, 95% CI 1.43 to 1.89; P < 0.001, I2 = 63%; 35 RCTs, 5165 women).
12Triglyceride levelsMeta-AnalysisCited 12×n=612 · large study2022
In plain English: Compared with metformin, the suitable supplemental dosage of myo-ins may be helpful in lowering levels of TG and avoiding adverse events (AEs).
Zhang JQ et al. · European review for medical and pharmacological sciences (2022)
Meta-analysis of 9 RCTs in 612 women with PCOS comparing myo-inositol with metformin.
Myo-inositol lowered triglycerides more than metformin (SMD -0.49, 95% CI -0.74 to -0.24) and caused fewer side effects (RR 0.14).
No significant differences in total testosterone, SHBG or other measures.
13Meta-Analysis2018
Laganà AS, Vitagliano A, Noventa M, Ambrosini G, D'Anna R · Arch Gynecol Obstet (2018)
No plain-language summary recorded for this citation — open the paper to read its abstract.
18Hormonal and metabolic parameters in PCOSMeta-AnalysisCited 14×n=1,088 · large study2023
In plain English: Our meta-analysis comparing hormonal and metabolic parameters between MET and MI did not show much significant difference, indicating both drugs are equally beneficial in improving metabolic and hormonal parameters in patients with PCOS.
Fatima K et al. · Irish journal of medical science (2023)
Meta-analysis of 8 RCTs in 1,088 women with PCOS comparing metformin (460) with myo-inositol (436), with 192 on both.
No significant difference between metformin and myo-inositol in BMI, fasting insulin, fasting blood sugar, HOMA index or LH/FSH ratio (for example fasting insulin SMD 0.00, 95% CI -0.26 to 0.27).